Bilobalide CAS: 33570-04-6

CAS NO: 33570-04-6
Bilobalide
Description Review
Description

Bilobalide is a natural compound found in the leaves of Ginkgo biloba, one of the oldest living tree species. It has been used for centuries in traditional Chinese medicine to treat various ailments, including asthma, bronchitis, and memory disorders. Bilobalide has also gained attention in recent years due to its potential therapeutic properties in the treatment of neurological disorders, such as Alzheimer's disease.

Chemical name: (5R,6S)-2,3,5,6-tetrahydroxy-4-methylchroman-7-one

Molecular formula: C15H18O8

Formula weight: 326.3 g/mol

CAS No: 33570-04-6

Top ten keywords from Google and synonyms:

  1. Bilobalide
  2. CAS 33570-04-6
  3. Ginkgo biloba
  4. Traditional Chinese medicine
  5. Neurological disorders
  6. Memory disorders
  7. Alzheimer's disease
  8. Anti-inflammatory
  9. Antioxidant
  10. Natural compound

Synonyms:

  • Bilobalid, (5R,6S)-2,3,5,6-tetrahydroxy-4-methylchroman-7-one, 33570-04-6

Health benefits of Bilobalide: Bilobalide has been shown to have several health benefits, primarily due to its anti-inflammatory and antioxidant properties. Traditional Chinese medicine has used it to treat various ailments, including asthma, bronchitis, and memory disorders. In modern research, bilobalide has demonstrated potential in treating neurological disorders such as Alzheimer's disease, as well as improving cognitive function and reducing inflammation.

Potential effects: Bilobalide has been found to have several potential effects on human health. It has been shown to improve cognitive function and memory retention, reduce inflammation, and protect against oxidative stress. Additionally, bilobalide has been studied for its potential neuroprotective effects and ability to improve blood circulation.

Product mechanism: The mechanisms underlying bilobalide's therapeutic effects are not fully understood. However, it is believed that its anti-inflammatory and antioxidant properties play a role in its ability to combat various diseases. Bilobalide has also been shown to modulate various signaling pathways involved in Alzheimer's disease and other neurological disorders.

Safety: Bilobalide is generally considered safe when taken orally or applied topically in appropriate doses. However, there is limited information on its safety during pregnancy or breastfeeding. Individuals with liver or kidney disease should use caution when taking bilobalide, as it may affect their condition. Additionally, some individuals may experience allergic reactions or gastrointestinal discomfort when taking bilobalide.

Side effects: In general, bilobalide does not cause significant side effects when taken in appropriate doses. However, some individuals may experience mild headaches, dizziness, or gastrointestinal discomfort when using bilobalide-containing products.

Dosing information: The optimal dosage of bilobalide varies depending on the intended use and formulation of the product. In general, oral doses range from 40-120 mg per day, while topical preparations may contain concentrations ranging from 0.5-5%. Careful attention should be paid to product labeling and instructions when using bilobalide-containing products.

Conclusion: Bilobalide is a natural compound found in the leaves of Ginkgo biloba, one of the oldest living tree species. It has been used for centuries in traditional Chinese medicine to treat various ailments, and has recently gained attention for its potential therapeutic properties in the treatment of neurological disorders such as Alzheimer's disease. While the mechanisms underlying its therapeutic effects are not fully understood, bilobalide's anti-inflammatory and antioxidant properties make it an intriguing area of study for researchers interested in natural remedies and alternative therapies. Overall, bilobalide represents a promising avenue for developing novel treatments for a variety of diseases and conditions

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us